Founded by Chinese biotech entrepreneur Wei William Cao, Suzhou, China headquartered Gracell Biotechnologies Co., Ltd (Gracell) is on a mission to bring best-in-class and economical cellular medicines to cancer patients. Dedicating capital, talent, and technology to resolve the cellular gene therapy industry’s major challenges including high production costs, lengthy manufacturing process, lack of off-the-shelf products, and short duration of therapeutic effects, the global clinical-stage biopharmaceutical company leverages its pioneering FastCAR and TruUCAR technology platforms. The company recently reported good news: its investigational treatment for multiple myeloma known as GCO12F has been assigned orphan drug status by the U.S. Food and Drug Administration (FDA).
TrialSite Investor Watch provides a brief overview of the company, its cell therapy technology, and the recent FDA news.
Summary of targeted condition
Multiple myeloma (MM) is the third most common type of blood cancer in the United States, originating from plasma cells, a type of immune cell that is typically responsible for secreting antibodies to fight infection. Globally, approximately 160,000 pat...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).